Trial Outcomes & Findings for Evaluation of Dryness in a Silicone Hydrogel Daily Disposable Contact Lens (NCT NCT04849780)

NCT ID: NCT04849780

Last Updated: 2022-10-10

Results Overview

Comfort was assessed using the Contact Lens User Experience™ (CLUE) questionnaire. CLUE is a validated patient-reported outcomes (PRO) questionnaire to assess patient-experience attributes of soft contact lenses (comfort, vision, handling, and packaging) in a contact-lens wearing population in the US, ages 18-65. Derived CLUE scores using Item Response Theory (IRT) follow a normal distribution with a population average score of 60 (SD 20), where higher scores indicate a more favorable/positive response with a range of 0-120. The change from baseline was calculated as 2-week follow-up minus baseline. The average change from baseline was reported for each arm. the change from baseline ranges from -120 to 120 where higher change from baseline comfort scores indicates a more favorable performance.

Recruitment status

COMPLETED

Study phase

NA

Target enrollment

95 participants

Primary outcome timeframe

Up to 2-Week Follow-up

Results posted on

2022-10-10

Participant Flow

A total of 95 subjects were enrolled in this study. Of those enrolled, 47 were randomized to Arm1 and dispensed at least one study lens, while 45 subjects were randomized to Arm 2 and were dispensed at least 1 study lenses. All dispensed subjects in Arm 1 completed the study while only 39 of those dispensed in Arm 2 completed the study. A total of 6 subjects were discontinued from Arm 2.

Participant milestones

Participant milestones
Measure
Arm 2
Subjects randomized to this Arm were dispensed their habitual lenses A for approximately 2 weeks, then returned for follow-up evaluation. Subjects were then dispensed senofilcon A for approximately 2 weeks, then returned for follow-up evaluation and were exited from the study.
Arm 1
Subjects randomized to this Arm were dispensed the senofilcon A for approximately 2 weeks, then returned for follow-up evaluation and were exited from the study.
Period 1
STARTED
45
47
Period 1
COMPLETED
41
47
Period 1
NOT COMPLETED
4
0
Period 2
STARTED
41
0
Period 2
COMPLETED
39
0
Period 2
NOT COMPLETED
2
0

Reasons for withdrawal

Reasons for withdrawal
Measure
Arm 2
Subjects randomized to this Arm were dispensed their habitual lenses A for approximately 2 weeks, then returned for follow-up evaluation. Subjects were then dispensed senofilcon A for approximately 2 weeks, then returned for follow-up evaluation and were exited from the study.
Arm 1
Subjects randomized to this Arm were dispensed the senofilcon A for approximately 2 weeks, then returned for follow-up evaluation and were exited from the study.
Period 1
Covid-19 Related
1
0
Period 1
Subject no longer meet eligibility criteria
3
0
Period 2
Subject no longer meet eligibility criteria
2
0

Baseline Characteristics

Evaluation of Dryness in a Silicone Hydrogel Daily Disposable Contact Lens

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Arm 1
n=47 Participants
Subjects randomized to this Arm were dispensed the senofilcon A for approximately 2 weeks, then returned for follow-up evaluation and were exited from the study.
Arm 2
n=45 Participants
Subjects randomized to this Arm were dispensed their habitual lenses A for approximately 2 weeks, then returned for follow-up evaluation. Subjects were then dispensed senofilcon A for approximately 2 weeks, then returned for follow-up evaluation and were exited from the study.
Total
n=92 Participants
Total of all reporting groups
Age, Continuous
34.6 years
STANDARD_DEVIATION 8.14 • n=93 Participants
34.0 years
STANDARD_DEVIATION 8.42 • n=4 Participants
34.3 years
STANDARD_DEVIATION 8.23 • n=27 Participants
Sex: Female, Male
Female
31 Participants
n=93 Participants
34 Participants
n=4 Participants
65 Participants
n=27 Participants
Sex: Female, Male
Male
16 Participants
n=93 Participants
11 Participants
n=4 Participants
27 Participants
n=27 Participants
Race/Ethnicity, Customized
Asian
1 participants
n=93 Participants
0 participants
n=4 Participants
1 participants
n=27 Participants
Race/Ethnicity, Customized
White
45 participants
n=93 Participants
45 participants
n=4 Participants
90 participants
n=27 Participants
Race/Ethnicity, Customized
Other
1 participants
n=93 Participants
0 participants
n=4 Participants
1 participants
n=27 Participants
Region of Enrollment
United States
47 participants
n=93 Participants
45 participants
n=4 Participants
92 participants
n=27 Participants

PRIMARY outcome

Timeframe: Up to 2-Week Follow-up

Population: Subjects that completed all required study visits without a major protocol deviation impacting a primary or secondary endpoint.

Comfort was assessed using the Contact Lens User Experience™ (CLUE) questionnaire. CLUE is a validated patient-reported outcomes (PRO) questionnaire to assess patient-experience attributes of soft contact lenses (comfort, vision, handling, and packaging) in a contact-lens wearing population in the US, ages 18-65. Derived CLUE scores using Item Response Theory (IRT) follow a normal distribution with a population average score of 60 (SD 20), where higher scores indicate a more favorable/positive response with a range of 0-120. The change from baseline was calculated as 2-week follow-up minus baseline. The average change from baseline was reported for each arm. the change from baseline ranges from -120 to 120 where higher change from baseline comfort scores indicates a more favorable performance.

Outcome measures

Outcome measures
Measure
Arm 1
n=46 Participants
Subjects that wore the senofilcon A lens for 2-weeks and then exited the study.
Arm 2 (Subjects' Own Contact Lens)
n=39 Participants
Subjects that wore their habitual lenses for 2-weeks and then wore senofilcon A for 2-weeks and then exited the study.
Change From Baseline Comfort Score
28.99 Units on a scale
Standard Deviation 26.766
-0.29 Units on a scale
Standard Deviation 10.245

SECONDARY outcome

Timeframe: Up to 2-Week Follow-up

Population: Subjects that completed all required study visits without a major protocol deviation impacting a primary or secondary endpoint.

The CLDEQ-8 is a validated outcome measure for soft contact lenses wearers. It has been highly correlated with habitual baseline status and change in overall opinion when subjects are refit with contact lenses. A CLDEQ-8 total score of ≥12 is proposed to identify contact lens wearers who could benefit from clinical management of their contact lens related symptoms. A three-point change in CLDEQ-8 total scores has also been shown to be clinically important. This study will include the symptomatic subjects who will have a CLDEQ total score of ≥15. CLDEQ-8 scores range from 0 to 30 where, higher CLDEQ-8 score indicates more dry eye symptoms with respect to contact lens wear. The change is calculated as 2-week minus Baseline. The change from baseline CLDEQ-8 score ranges from -30 to 30 where lower change from baseline CLDEQ-8 scores indicate better performance. The average change in CLDEQ-8 for each arm was reported.

Outcome measures

Outcome measures
Measure
Arm 1
n=46 Participants
Subjects that wore the senofilcon A lens for 2-weeks and then exited the study.
Arm 2 (Subjects' Own Contact Lens)
n=39 Participants
Subjects that wore their habitual lenses for 2-weeks and then wore senofilcon A for 2-weeks and then exited the study.
Change From Baseline CLDEQ-8 Score
-10.83 Unit on a scale
Standard Deviation 6.631
-1.23 Unit on a scale
Standard Deviation 3.638

SECONDARY outcome

Timeframe: 2-Week Follow-up

Population: Subjects randomized to Arm 2 and completed all required study visits without a major protocol deviation impacting a primary or secondary endpoint.

Comfort was assessed using the Contact Lens User Experience™ (CLUE) questionnaire. CLUE is a validated patient-reported outcomes (PRO) questionnaire to assess patient-experience attributes of soft contact lenses (comfort, vision, handling, and packaging) in a contact-lens wearing population in the US, ages 18-65. Derived CLUE scores using Item Response Theory (IRT) follow a normal distribution with a population average score of 60 (SD 20), where higher scores indicate a more favorable/positive response with a range of 0-120. The average comfort score was reported for each group within Arm 2 only.

Outcome measures

Outcome measures
Measure
Arm 1
n=39 Participants
Subjects that wore the senofilcon A lens for 2-weeks and then exited the study.
Arm 2 (Subjects' Own Contact Lens)
n=39 Participants
Subjects that wore their habitual lenses for 2-weeks and then wore senofilcon A for 2-weeks and then exited the study.
Comfort Score
55.88 Unit on a scale
Standard Deviation 25.721
29.69 Unit on a scale
Standard Deviation 13.849

SECONDARY outcome

Timeframe: 2-Week Follow-up

Population: Subjects randomized to Arm 2 and completed all required study visits without a major protocol deviation impacting a primary or secondary endpoint.

The CLDEQ-8 is a validated outcome measure for soft contact lenses wearers. It has been highly correlated with habitual baseline status and change in overall opinion when subjects are refit with contact lenses. A CLDEQ-8 total score of ≥12 is proposed to identify contact lens wearers who could benefit from clinical management of their contact lens related symptoms. A three-point change in CLDEQ-8 total scores has also been shown to be clinically important. This study will include the symptomatic subjects who will have a CLDEQ total score of ≥15. CLDEQ-8 scores range from 0 to 30 where, higher CLDEQ-8 score indicates more dry eye symptoms with respect to contact lens wear. The average CLDEQ-8 for each arm was reported.

Outcome measures

Outcome measures
Measure
Arm 1
n=39 Participants
Subjects that wore the senofilcon A lens for 2-weeks and then exited the study.
Arm 2 (Subjects' Own Contact Lens)
n=39 Participants
Subjects that wore their habitual lenses for 2-weeks and then wore senofilcon A for 2-weeks and then exited the study.
CLDEQ-8 Score
12.46 Unit on a scale
Standard Deviation 6.078
21.18 Unit on a scale
Standard Deviation 3.698

Adverse Events

Senofilcon A

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Nelfilcon A

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Delfilcon A

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Somofilcon A

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Stenofilcon A

Serious events: 0 serious events
Other events: 1 other events
Deaths: 0 deaths

Etafilcon A

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Other adverse events
Measure
Senofilcon A
n=88 participants at risk
Subjects that wore the senofilcon A lens in either Arm of the study.
Nelfilcon A
n=11 participants at risk
Subjects that wore the nelfilcon A lens during the first period in Arm 2
Delfilcon A
n=10 participants at risk
Subjects that wore the delfilcon A lens during the first period in Arm 2
Somofilcon A
n=5 participants at risk
Subjects that wore the somofilcon A lens during the first period in Arm 2
Stenofilcon A
n=2 participants at risk
Subjects that wore the stenofilcon A lens during the first period in Arm 2
Etafilcon A
n=17 participants at risk
Subjects that wore the etafilcon A lens during the first period in Arm 2
Infections and infestations
Covid - 19
0.00%
0/88 • Throughout the entire duration of the study. For subject in Arm 1 their study duration was approximately 2-weeks while subjects in Arm 2 study duration was approximately 1-month.
0.00%
0/11 • Throughout the entire duration of the study. For subject in Arm 1 their study duration was approximately 2-weeks while subjects in Arm 2 study duration was approximately 1-month.
0.00%
0/10 • Throughout the entire duration of the study. For subject in Arm 1 their study duration was approximately 2-weeks while subjects in Arm 2 study duration was approximately 1-month.
0.00%
0/5 • Throughout the entire duration of the study. For subject in Arm 1 their study duration was approximately 2-weeks while subjects in Arm 2 study duration was approximately 1-month.
50.0%
1/2 • Throughout the entire duration of the study. For subject in Arm 1 their study duration was approximately 2-weeks while subjects in Arm 2 study duration was approximately 1-month.
0.00%
0/17 • Throughout the entire duration of the study. For subject in Arm 1 their study duration was approximately 2-weeks while subjects in Arm 2 study duration was approximately 1-month.

Additional Information

John R. Buch, OD, MS, FAAO

Johnson & Johnson Vision Care, Inc.

Phone: 1-800-846-2020

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place

Restriction type: GT60